Johnson & Johnson vaccine, Aifa green light at second mRna dose

Johnson & Johnson vaccine, green light from the Technical Scientific Commission of the Italian Medicines Agency (Aifa) at the booster dose for those who have received the single-dose anti-Covid vaccine. The CTS, expressing itself at the request of the Ministry of Health, considered that “for subjects vaccinated with Covid-19 Janssen it is appropriate to administer a heterologous booster dose with mRna vaccine (in the dosages authorized for the booster dose) starting from 6 months from the first dose “. Read also “Given that the Covid-19 Janssen vaccine is the only vaccine authorized with a single-dose schedule and that, in the vaccination field, a booster dose, or booster, can be considered a consolidated strategy for most vaccines – reads in an AIFA note – the opportunity to predict a booster dose appears supported by a solid rationale. The most recent evidence confirms the efficacy of a booster dose (especially with mRna vaccine) in enhancing the immune response to the Covid-19 vaccine Janssen “. Furthermore,” the available data indicate a substantial stability of the immune response, both humoral and cellular, up to 8 months after the administration of a dose of Janssen vaccine. Protection against serious illness, hospitalization or death is also substantially stable. up to at least 6 months after vaccination “, the Cts of Aifa found,” on the basis of the in-depth investigation “carried out by the agency’s experts, i since yesterday to evaluate the request of the Ministry of Health on the recall for vaccinated with a single dose of Janssen vaccine and on the relative timing. “At the same time, however, a slow decline in vaccination efficacy is observed over the months – it is emphasized – towards mild / moderate forms of the disease “.